●590 patients from the Amsterdam Dementia Cohort with a clinical diagnosis in the frontotemporal lobar degeneration (FTLD) spectrum

●Subset of 54 patients with pathological confirmation of FTLD as the primary pathology

 

Biomarkers

●Amyloid status based on available biomarkers (hierarchical):

    1. Amyloid PET, OR

    2. CSF p-tau/Aβ42 ratio, OR

    3. CSF Aβ42

 

Definitions

●Survival: interval from first memory clinic visit to death

●Censoring: at last clinical follow-up

 

Analysis

●Cox proportional hazards models: associations between amyloid status and survival

●Stratification by clinical subtype for the four largest subgroups

 

Overall median survival 4.7 [IQR 2.7-7.2] years

The association between Aβ status and survival differed significantly across clinical subtypes (p < 0.001)

 

CONCLUSION

1.van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, van der Flier WM, Teunissen CE, Mollenhauer B, Fladby T, Kramberger MG, Bonanni L, Lemstra AW; European DLB consortium. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. J Alzheimers Dis. 2016 Aug 18;54(1):287-95. doi: 10.3233/JAD-160322.

2.Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, Lee EB, Van Deerlin VM, Lopez OL, Kofler JK, Nelson PT, Jicha GA, Woltjer R, Quinn JF, Kaye J, Leverenz JB, Tsuang D, Longfellow K, Yearout D, Kukull W, Keene CD, Montine TJ, Zabetian CP, Trojanowski JQ. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 2017 Jan;16(1):55-65. doi: 10.1016/S1474-4422(16)30291-5.